We turn research and knowledge into products and services that benefit society

Banner for The Innovation Prize

Latest news

Latest news

Here you can read the latest news regarding Inven2s portfolio businesses, innovation projects and clinical studies. Every month we write longer articles where we interview current researchers and clinicians..
Summary of the year 2023

Summary of the year 2023

Inven2 is grateful to everyone who has contributed to building business and helping patients through new inventions, clarification, clinical...

read more



There are no upcoming events at this time.

Licensing opportunities

Licensing opportunities

Here you will find an overview of license opertunities. We are actively looking for industry partners who may consider licensing these technologies to further develop them into products or services.

Therapeutic regulation of WNT/YAP-signaling through a potent and specific tankyrase inhibitor

A class of novel WNT/YAP inhibitor compounds exhibiting high specificity for tankyrase and demonstrated proof of concept in mouse models for several cancer indications. Read more

An optimized engineered albumin for half-life extension and mucosal delivery of biologics

An engineered human albumin variant with extended in vivo half-life. Read more

A versatile improved antibody Fc technology platform

A unique and versatile antibody Fc technology platform (“REW”). Read more

AnaConDebt – Analysis of Contagious technical Debt

Technical debt in software development consists of sub-optimal design solutions that are beneficial in the short term, but create costly negative impact in the long run, e.g. costly maintenance changes and impossibility to evolve the system. Read more


Inven2’s core business is innovation. We contribute in the process of commersialising good ideas from talented researchers, turning them into products and services that make a difference.

Clinical studies

Inven2 work closely with hospitals and companies to make sure clinical studies are completed quick and efficient, to the best for Norwegian patients.

Key figures 2010 – 2023

# Ideas evaulated (DOFI)

# Companies established

# Licence agreements

# New patent applications

MNOK transferred back to research, innovation and inventors

# Clinical Trials managed

Portfolio businesses

Portfolio businesses

Inven2 has a portfolio comprising 50 companies. We have established them either on our own or alongside investors and others. The point of departure for the companies are research results from innovative researchers. The portfolio value in December 2023 is NOK 11 billion, but this will vary with the value of the individual company and how long we are shareholders in the most valuable companies.

Products on the market

Products on the market

Inven2 has contributed to many products and services that have served society well through licensing to industry or business start-ups within a range of technology fields. What follows is a selection of them.